Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 7% – Here’s Why

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shares dropped 7% during trading on Wednesday . The stock traded as low as $2.19 and last traded at $2.1680. 714,216 shares traded hands during trading, a decline of 59% from the average session volume of 1,727,052 shares. The stock had previously closed at $2.33.

Autolus Therapeutics News Summary

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations: Autolus reported a loss of $0.15 per share, better than the $0.21 loss analysts expected. Revenue reached $45.69 million versus the $38.56 million consensus estimate, providing evidence of better-than-anticipated commercial progress. Autolus Second-Quarter 2026 Results
• Positive Sentiment: Higher AUCATZYL guidance signals launch momentum: Management raised its outlook for AUCATZYL, helping reinforce expectations for stronger sales growth as the therapy’s commercial rollout progresses. The guidance increase was identified as a key reason shares rose following the results. Autolus Shares and AUCATZYL Guidance
• Neutral Sentiment: Short-interest data provides no usable signal: The report lists short interest at zero shares on both July 27 and August 11, with a zero-day days-to-cover ratio. Because the figures produce an invalid percentage change and appear inconsistent with a normally reported short-interest dataset, they do not meaningfully indicate changing bearish positioning.
• Negative Sentiment: Autolus remains unprofitable: Despite beating estimates, the company continues to post losses, with a reported negative net margin of 311.98% and negative return on equity of 128.59%. Continued cash needs and execution risks remain important concerns as the company invests in AUCATZYL’s commercialization. Autolus Q2 2026 Earnings Call Transcript

Analyst Ratings Changes

Several research analysts have recently weighed in on AUTL shares. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Stock Down 7.5%

The company’s fifty day moving average is $1.61 and its 200-day moving average is $1.55. The company has a market cap of $573.57 million, a PE ratio of -1.98 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The firm had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Equities research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. Syncona Portfolio Ltd bought a new position in shares of Autolus Therapeutics during the 2nd quarter valued at approximately $26,625,152,000. Schroder Investment Management Group raised its stake in Autolus Therapeutics by 133.7% during the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock worth $13,409,000 after acquiring an additional 4,824,763 shares during the period. Mak Capital One LLC raised its stake in Autolus Therapeutics by 15.3% during the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after acquiring an additional 3,987,727 shares during the period. Armistice Capital LLC lifted its holdings in Autolus Therapeutics by 30.0% during the third quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.